Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Broadens Cervical Cancer Testing Lineup With MTM Acquisition

This article was originally published in The Gray Sheet

Executive Summary

Roche will seek PMA approval for MTM Laboratories’ cervical cancer tests following acquisition of the diagnostics firm for up to $270 million in a deal announced July 19.

You may also be interested in...



Ventana President Mara Aspinall: An Interview With “The Pink Sheet” DAILY

In the midst of a busy January – in which Ventana has signed four publicly disclosed deals to develop companion diagnostics with pharma partners – Ventana President Mara Aspinall talked with “The Pink Sheet” DAILY about pharma’s evolving attitude on personalized medicine, sharing value for joint projects and how Ventana is positioning itself to be the partner of choice for pharma.

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2011

Medical device companies raised a total of $906 million in Q3, while in vitro diagnostic/research developers took in $72 million. The top M&As in each segment were private buyouts of public companies: Kinetic Concepts for $6.3 billion and Immucor for $1.9 billion.

Roche Ramps Up Sales Force For U.S. Launch Of HPV Test

Roche has been hiring additional sales reps and training its existing sales force in preparation for the U.S. launch of its cobas HPV test to identify women at high risk of developing cervical cancer.

Latest News
See All
UsernamePublicRestriction

Register

MT030378

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel